H.R. 9599 · 119th Congress · Health
SECURE 340B Act
- IntroducedJul 6, 2026 Done
- CommitteeReferred to 3 committees Current stage
- House floorNot yet Not reached yet
- Senate floorNot yet Not reached yet
- Chambers agreeNot yet Not reached yet
- PresidentNot yet Not reached yet
What it does
The Congressional Research Service hasn’t published a summary of this bill. Read the full text on Congress.gov.Who lobbies on it
17 organizations, more than 98% of House bills · 19 filings · Q3 2026These 17 organizations’ PACs gave $339K to 9 of the 9 members sponsoring or cosponsoring H.R. 9599 in the 2025–26 election cycle.
One square per quarter since introduction, oldest left. Filled = named it that quarter.
-
Pharmaceutical Research and Manufacturers of America
1 of 1 quarter
“…H.R. 9599: SECURE 340B Act H.R. 9661: Expedited Access to Biosimilars Act 340B Drug Pricing Integrity and Affordability for Patients Act (draft) SECURE Act of 2026 (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (Public Law 117-169)…”
$26.6M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
American Hospital Association
1 of 1 quarter
“H.R. 4581 / S.2372, 340B PATIENTS Act, all provisions; H.R. 5256, 340B Access Act, all provisions; DRAFT, 340B Drug Pricing Integrity and Affordability for Patients Act, all provisions; H.R. 9599, Strengthening the Exercise of Controls and Upgrading Requirements for Efficiency in 340B Act (SECURE 340B Act), all…”
$14.4M lobbying spend in 2026 to date, all issuesQ3 2026 filing
-
Pfizer Inc.
1 of 1 quarter
“H.R. 5256 - 340B ACCESS Act H.R. 9599 - SECURE 340B Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform Hospital Outpatient Prospective Payment System (OPPS) Proposed Rule/Essential Medicines PBM Reform Drug Pricing…”
$9.9M lobbying spend in 2026 to date, all issuesQ3 2026 filing
14 more organizations, every filingPROUpgrade
Organizations that named H.R. 9599 in a quarterly lobbying report. Covers organizations with a PAC on file; reports from organizations without one aren’t loaded yet. Spend is the organization’s total across all issues: reports don’t split spending by bill. “Gave to” means the organization’s PAC gave to the member’s campaign in the 2025–26 cycle, net of refunds; it doesn’t mean the money was about this bill. Organizations may lobby for, against, or to change a bill; filings don’t say which. Source: Senate lobbying disclosures (LD-2) from lda.gov; PAC gifts from FEC filings; quotes are word for word from the “specific lobbying issues” field; where a filing lists many bills, the quote starts where it names this one.
Actions
2 actions · newest first- Jul 6, 2026Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- Jul 6, 2026Introduced in House
What members said about it
-
Dr. Joyce, Rep. Peters Lead Bipartisan Proposal to Restore Clarity to the 340B Program
Today, Congressman John Joyce, M.D. (PA-13) and Congressman Scott Peters (CA-50) introduced H.R. 9599, the SECURE 340B Act, the first-ever comprehensive, bipartisan proposal to modernize the 340B Drug Pricing Program since its creation in…
“Since its establishment, the 340B program has served as a critical lifeline for low-income patients to access lifesaving medications.”